State of art in the chemistry of nucleoside-based Pt(II) complexes

D’Errico, Stefano; Falanga, Andrea Patrizia; Greco, Francesca; Piccialli, Gennaro; Oliviero, Giorgia; Borbone, Nicola

doi:10.1016/j.bioorg.2022.106325

Cited by 3 publications

(3 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since a few recent reviews dealing with cisplatin [111] and other platinum complexes [112] bearing nucleic acid derivatives have been published, we have focused our attention on other metal centres. The main contributions in this research area involve the use of ruthenium complexes.…”

Section: Metal-based Lipid and Nucleic Acid Drug Conjugatesmentioning

confidence: 99%

“…The last topic presented in this review concerns vitamin metal complexes. Vitamins are essential organic molecules with a specific role in several phases of cell Since a few recent reviews dealing with cisplatin [111] and other platinum complexes [112] bearing nucleic acid derivatives have been published, we have focused our attention on other metal centres. The main contributions in this research area involve the use of ruthenium complexes.…”

Section: Metal-based Vitamin Drug Conjugatesmentioning

confidence: 99%

See 1 more Smart Citation

Recent Advances in Bioconjugated Transition Metal Complexes for Cancer Therapy

2023

View full text Add to dashboard Cite

The introduction of biologically relevant organic moieties in the coordination sphere of transition metal complexes has recently become a well-established strategy to increase the selectivity and biocompatibility of metallodrugs. In this review, the major advances achieved in this area of research in the last three years are described in detail. Particular attention is given to the metal complexes bearing the main biomolecules of life: carbohydrates, lipids, nucleotides, proteins and vitamins. Each paragraph summarizes the synthetic strategy employed to obtain the complexes of interest as well as the most interesting biological results obtained with these potential metallodrugs. Moreover, the structure–activity relationships observed by the different research groups are described and discussed, with the goal of suggesting to the reader the ligand/metal centre combinations that provide the most promising results in the fight against cancer. Some of the compounds examined in this review as well as other bioconjugated metal complexes published in recent decades exhibit interesting selectivity towards cancer cells over normal ones and a specific mode of action. These latter aspects are the basis of what is commonly known as anticancer target therapy.

show abstract

Section: Metal-based Lipid and Nucleic Acid Drug Conjugatesmentioning

confidence: 99%

Section: Metal-based Vitamin Drug Conjugatesmentioning

confidence: 99%

Recent Advances in Bioconjugated Transition Metal Complexes for Cancer Therapy

2023

View full text Add to dashboard Cite

show abstract

“…In light of the significance of such  - interactions, platinum compounds having nucleobase ligands would seem to be ideal anticancer agents, since the nucleobase ligand would naturally intercalate between base pair layers in the DNA. Indeed, various platinum(II) complexes of nucleotides, 12 nucleosides, 13,14,15 and nucleobase derivatives 16 have been reported as highly lethal to different kinds of cancers. Several platinum(II) compounds having adenosine 17,18 or an adenine derivative 19,20,21,22,23,24,25,26,27,28,29,30 as an ancillary ligand have also been reported to be highly cytotoxic toward various cancer cell lines.…”

Section: Introductionmentioning

confidence: 99%

Synthesis, Structure and Anticancer Activity of a Dinuclear Organoplatinum(IV) Complex Stabilized by Adenine

O'Brien,

Howard,

Wheeler

2024

Preprint

View full text Add to dashboard Cite

The dinuclear organoplatinum(IV) compound {Pt(CH3)3}2(μ-I)2(μ-adenine) (abbreviated Pt2ad), obtained by treating cubic [Pt(CH3)3(μ3-I)]4 with two equivalents of adenine, was isolated and structurally characterized by single crystal X-ray diffraction. The National Cancer Institute Developmental Therapeutics Program′s in vitro sulforhodamine B assays showed Pt2ad to be particularly cytotoxic against central nervous system cancer cell line SF-539, and human renal carcinoma cell line RXF-393. Furthermore, Pt2ad displayed some degree of cytotoxicity against non-small cell lung cancer (NCI-H522), colon cancer (HCC-2998, HCT-116, HT29, and SW-620), melanoma (LOX-IMVI, MALME-3M, M14, MDA-MB-435, SK-MEL-28, and UACC-62), ovarian cancer (OVCAR-5), renal carcinoma (A498), breast cancer (BT-549 and MDA-MB-468), and triple-negative breast cancer (MDA-MB-231).

show abstract